Florence van Hunsel
Florence van Hunsel
Head Signal detection, Netherlands Pharmacovigilance Centre Lareb
Geverifieerd e-mailadres voor lareb.nl
Geciteerd door
Geciteerd door
Adverse drug reaction reporting by patients in The Netherlands three years of experience
J de Langen, F van Hunsel, A Passier, L de Jong-van den Berg, ...
Drug Safety 31 (6), 515-524, 2008
Experiences with adverse drug reaction reporting by patients
F van Hunsel, L Härmark, S Pal, S Olsson, K van Grootheest
Drug safety 35 (1), 45-60, 2012
Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an …
F Van Hunsel, A Passier, K Van Grootheest
British journal of clinical pharmacology 67 (5), 558-564, 2009
Acute effects of nicotine on attention and response inhibition
EM Bekker, KBE Böcker, F Van Hunsel, MC Van Den Berg, JL Kenemans
Pharmacology Biochemistry and Behavior 82 (3), 539-548, 2005
Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
F van Hunsel, C van der Welle, A Passier, E van Puijenbroek, ...
European journal of clinical pharmacology 66 (11), 1143-1150, 2010
ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems
L Härmark, F van Hunsel, B Grundmark
Drug safety 38 (4), 337-347, 2015
The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case–control study
F van Hunsel, A Talsma, E van Puijenbroek, L de Jong‐van den Berg, ...
pharmacoepidemiology and drug safety 20 (3), 286-291, 2011
Adverse drug reactions of montelukast in children and adults
MG Haarman, F van Hunsel, TW de Vries
Pharmacology research & perspectives 5 (5), e00341, 2017
Adverse drug reaction reports of patients and healthcare professionals—differences in reported information
L Rolfes, F van Hunsel, S Wilkes, K van Grootheest, E van Puijenbroek
Pharmacoepidemiology and drug safety 24 (2), 152-158, 2015
The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis
L Rolfes, F van Hunsel, L van der Linden, K Taxis, E van Puijenbroek
Drug safety 40 (7), 607-614, 2017
Adverse food–drug interactions
A de Boer, F Van Hunsel, A Bast
Regulatory Toxicology and Pharmacology 73 (3), 859-865, 2015
The impact of experiencing adverse drug reactions on the patient’s quality of life: a retrospective cross-sectional study in the Netherlands
L Rolfes, F van Hunsel, K Taxis, E van Puijenbroek
Drug safety 39 (8), 769-776, 2016
Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre
S Watson, RE Chandler, H Taavola, L Härmark, B Grundmark, A Zekarias, ...
Drug safety 41 (2), 203-212, 2018
The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015
F van Hunsel, S de Waal, L Härmark
Pharmacoepidemiology and drug safety 26 (8), 977-983, 2017
Are consumers ready to take part in the Pharmacovigilance System?—A Portuguese preliminary study concerning ADR reporting
C Matos, F van Hunsel, J Joaquim
European journal of clinical pharmacology 71 (7), 883-890, 2015
Important information regarding reporting of adverse drug reactions: a qualitative study
L Rolfes, S Wilkes, F van Hunsel, E van Puijenbroek, K van Grootheest
International Journal of Pharmacy Practice 22 (3), 231-233, 2014
Patient reporting of adverse drug reactions: an international survey of national competent authorities’ views and needs
C Matos, L Härmark, F van Hunsel
Drug safety 39 (11), 1105-1116, 2016
What motivates patients to report an adverse drug reaction?
FPAM van Hunsel, EAAM ten Berge, SD Borgsteede, K van Grootheest
Annals of Pharmacotherapy 44 (5), 936-937, 2010
Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring
L Härmark, F van Hunsel, E Hak, K van Grootheest
Vaccine 29 (10), 1941-1947, 2011
Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins
F van Hunsel, E van Puijenbroek, L de Jong‐van den Berg, ...
Pharmacoepidemiology and drug safety 19 (1), 26-32, 2010
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20